**Kaku 2009**

1 **Treatments**

*Studied treatment*  additional mitiglinide 5 or 10 mg tid

*Control treatment*  placebo on top pioglitazone

*Concomittant treatments*  -

2 **Patients**

*Patients*  Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy

*Inclusion criteria*  -

*Exclusion criteria*  -

3 **Methods**

*Blinding*  multicenter

*Design*  Parallel groups

*Centers*  -

*Geographical area*  -

*Sizes*  -9/-9

4 **Results**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 **References**